Rapid in-situ gel forming compositions prepared via reaction of vinyl sulfone derivatized hyaluronic acid with thiol derivatized polyethylene glycol at alkaline pH
The present application provides rapid-gelling, sprayable hyaluronic-acid based compositions, kits, related methods, precursor formulations, and uses thereof.
1. A kit comprising components for preparing a rapid-gelling composition, the kit comprising:
(i) a first container comprising an aqueous solution of vinyl sulfone-derivatized hyaluronic acid (“HA-VS”) at a concentration of from about 10-300 mg/mL, where HA-VS is (2-(vinylsulfonyl)ethoxy)hyaluronic acid, and the HA-VS has from about 11-35% of its hydroxyl groups transformed to 2-(vinylsulfonyl)ethoxy groups,
(ii) a second container comprising a thiol-functionalized polyethylene glycol having from 2 to 8 thiol groups, and
(iii) a third container comprising a 30-1000 mM buffer solution at a pH ranging from about 8.0-10.5, in an amount effective, when mixed with the contents of the first and second containers, to provide a solution having a HA-VS concentration of 2-8% (w/v) and a thiol-functionalized polyethylene glycol concentration of 2-8% (w/v),
wherein the components of the first, second and third containers, when combined, are effective to form a gel within about 10 minutes of mixing.
2. A rapid-gelling, liquid composition formed from the combination of
(i) an aqueous solution of vinyl sulfone-derivatized hyaluronic acid (“HA-VS”) at a concentration of from about 10-300 mg/mL, where HA-VS is (2-(vinylsulfonyl)ethoxy)hyaluronic acid, and the HA-VS has from about 11-35% of its hydroxyl groups transformed to 2-(vinylsulfonyl)ethoxy groups, (ii) a thiol-functionalized polyethylene glycol having from 2 to 8 thiol groups, and (iii) a 30-1000 mM buffer solution at a pH ranging from about 8.0-10.5,
where the concentration of the thiol-functionalized polyethylene glycol in the liquid composition ranges from about 4-300 mg/mL, and
the liquid composition is effective to form a gel within from about ten minutes of mixing components (i), (ii) and (iii).
3. The kit of claim 1 , wherein the vinyl sulfone-derivatized hyaluronic acid has from about 15-20%, of its hydroxyl groups substituted with vinyl sulfone.
4. The kit of claim 1 , wherein the thiol-functionalized polyethylene glycol has a number of thiol groups selected from the group consisting of 2, 3, and 4.
5. The kit of claim 1 , wherein the vinyl sulfone-derivatized hyaluronic acid has an average molecular weight ranging from about 20,000 to about 200,000 daltons.
6. The kit of claim 1 , wherein the thiol-functionalized polyethylene glycol is linear or branched.
7. The kit of claim 1 , wherein the thiol-functionalized polyethylene glycol has an average molecular weight of from about 1,000 to about 10,000 daltons.
8. The kit of claim 1 , wherein the molecular weight of the thiol-functionalized polyethylene glycol is less than the molecular weight of the vinyl sulfone-derivatized hyaluronic acid.
9. The kit of claim 1 , wherein the aqueous solution of vinyl sulfone-derivatized hyaluronic acid (“HA-VS”) has a concentration ranging from about 20-200 mg/mL.
10. The kit of claim 1 , wherein the thiol-functionalized polyethylene glycol is in the form of a powder.
11. The kit of claim 1 , wherein the amount of thiol-functionalized polyethylene glycol relative to vinyl sulfone-derivatized hyaluronic acid ranges from about 1:1 (w/w) to about 0.4:1 (w/w).
12. The kit of claim 1 , wherein either one of the first, second or third containers further comprises a bioactive agent or the kit further comprises a fourth container comprising a bioactive agent.
13. The liquid composition of claim 2 , further comprising a bioactive agent.
14. The liquid composition of claim 13 , wherein the bioactive agent is a corticosteroid selected from the group consisting of triamcinolone, triamcinolone acetonide or triamcinolone hexacetonide.
15. The kit of claim 12 , wherein the bioactive agent is a corticosteroid selected from the group consisting of triamcinolone, triamcinolone acetonide and triamcinolone hexacetonide.
16. The kit of claim 1 , wherein the first container further comprises from about 0.1 weight % to about 3.5 weight percent of the thiol-functionalized polyethylene glycol relative to the vinyl sulfone-derivatized hyaluronic acid (w/w).
17. A method of forming a liquid composition capable of rapid in-situ gel formation, comprising:
(i) adding a thiol-functionalized polyethylene glycol having from 2 to 8 thiol groups to a aqueous solution of vinyl sulfone-derivatized hyaluronic acid (“HA-VS”) having a concentration of from about 4-300 mg/mL, where HA-VS is (2-(vinylsulfonyl)ethoxy)hyaluronic acid, and the HA-VS has from about 11-35% of its hydroxyl groups transformed to 2-(vinylsulfonyl)ethoxy groups, to thereby dissolve the thiol-functionalized polyethylene glycol to form a vinyl sulfone-derivatized hyaluronic acid-thiol-functionalized polyethylene glycol-containing solution, and
(ii) combining the solution from step (i) with a 30-1000 mM buffer solution at a pH ranging from about 8.0-10.5, to thereby form a liquid composition having a HA-VS concentration of 2-8% (w/v) and a thiol-functionalized polyethylene glycol concentration of 2-8% (w/v),
wherein the liquid composition is effective to form a gel within about 10 minutes of combining.
18. The method of claim 17 , wherein:
(i) the vinyl sulfone-derivatized hyaluronic acid has an average molecular weight ranging from about 20,000 to about 200,000 daltons; and/or
(ii) the aqueous solution of the vinyl sulfone-derivatized hyaluronic acid (“HA-VS”) has a concentration ranging from about 20-200 mg/mL; and/or
(iii) the molecular weight of the thiol-functionalized polyethylene glycol is less than the molecular weight of the vinyl sulfone-derivatized hyaluronic acid; and/or
(iv) the amount of thiol-functionalized polyethylene glycol relative to vinyl sulfone-derivatized hyaluronic acid ranges from about 1:1 (w/w) to about 0.4:1 (w/w).
19. The method of claim 17 , further comprising adding a bioactive agent to the vinyl sulfone-derivatized hyaluronic acid-thiol-functionalized polyethylene glycol-containing solution of step (i), or to the buffer solution from step (ii) prior to the combining, or to the liquid composition formed in step (ii).
20. The method of claim 19 , wherein the bioactive agent is a corticosteroid selected from the group consisting of triamcinolone, triamcinolone acetonide or triamcinolone hexacetonide.
21. A method of forming a liquid composition capable of rapid, in-situ gel formation, comprising:
(i) adding a portion of an overall amount of thiol-functionalized polyethylene glycol to an aqueous solution of vinyl sulfone-derivatized hyaluronic acid (“HA-VS”) having a concentration of from about 10-300 mg/mL, where HA-VS is (2-(vinylsulfonyl)ethoxy)hyaluronic acid, and the HA-VS has from about 11-35% of its hydroxyl groups transformed to 2-(vinylsulfonyl)ethoxy groups, to thereby form a solution,
(ii) optionally sterilizing the solution from step (i),
(iii) adding to the solution from step (i) or step (ii) if carried out, the remaining amount of thiol-functionalized polyethylene glycol, where the thiol-functionalized polyethylene glycol has from 2 to 8 thiol groups, to thereby dissolve the remaining amount of thiol-functionalized polyethylene glycol to form a vinyl sulfone-derivatized hyaluronic acid-thiol-functionalized polyethylene glycol-containing solution, and
(iv) mixing the vinyl sulfone-derivatized hyaluronic acid-thiol-functionalized polyethylene glycol-containing solution with a 30-1000 mM buffer solution at a pH ranging from about 8.0-10.5,
to thereby form a liquid composition having a HA-VS concentration of 2-8% (w/v) and a thiol-functionalized polyethylene glycol concentration of 2-8% (w/v), to thereby form a liquid composition effective to form a gel within about 10 minutes of mixing.
22. The method of claim 21 , wherein the portion of thiol-functionalized polyethylene glycol in step (i) comprises from about 0.1 weight % to about 3.5 weight percent thiol-functionalized polyethylene glycol relative to the vinyl sulfone-derivatized hyaluronic acid (w/w).
23. The method of claim 21 , further comprising adding a bioactive agent to the solution of step (i), or to the vinyl sulfone-derivatized hyaluronic acid-thiol-functionalized polyethylene glycol-containing solution from step (iii), or to the buffer solution from step (iv) prior to mixing, or to the liquid composition formed in step (iv).
24. The method of claim 23 , wherein the bioactive agent is a corticosteroid selected from the group consisting of triamcinolone, triamcinolone acetonide and triamcinolone hexacetonide.
25. A method of for treating a condition selected from the group of osteoarthritis, rheumatoid arthritis, a wound and reduction of surgical adhesions, by applying the liquid composition of claim 2 to a body site in a subject suffering from the condition.
26. The kit of claim 1 , wherein one or more of the kit components is sterile.
27. The liquid composition of claim 2 , having one or more components in sterile form.
28. The method of claim 21 , comprising (ii) sterilizing the solution from step (i) and/or where either one or both of the thiol-functionalized polyethylene glycol from step (iii) and the buffer solution is sterile.
29. A hydrogel formed from the liquid composition of claim 2 .
30. A method for repairing tissue of a joint during arthroscopic or open joint surgery by applying the liquid composition of claim 2 to the tissue.